Post Profile

Bristol lung-cancer setback puts rival Merck drug in driver seat

(Reuters) - New data is likely to prompt doctors to abandon Bristol-Myers Squibb's immunotherapy Opdivo in favor of Merck & Co's rival Keytruda in a large segment of the lucrative lung cancer market, analysts said on Monday. The results of a closely watched clinical trial sent Bristol's shares plunging 10 percent. The data, presented at a medical meeting on Sunday, showed that lung cancer patients fared worse on Opdivo than those on chemotherapy.
read more


Related Posts

Merck's Keytruda achieves 24 percent response in bladder cancer study

Health : Reuters: Health

(Reuters) - Merck & Co's immunotherapy Keytruda proved effective as an initial treatment for nearly a quarter of patients with advanced bladder cancer too frail for standard cisplatin chemotherapy, according to interim results from ...

Bristol drug flop opens big cancer opportunity: AstraZeneca CEO

Health : Reuters: Health

COPENHAGEN (Reuters) - The failure of Bristol-Myers Squibb's blockbuster Opdivo immunotherapy in previously untreated lung cancer patients has opened up the market for AstraZeneca, its chief executive believes.

Merck drug shines in lung cancer and also works with chemo

Health : Reuters: Health

COPENHAGEN (Reuters) - Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemot...

Bristol's Opdivo Disappoints in Lung Cancer, While Merck's Keytruda Surprises

Business & Finance : Forbes: Business

FindTheCompany | Graphiq Shares of Bristol-Myers Squibb have fallen 26% since August, when a large study of lung cancer patients failed to demonstrate that its breakthrough cancer drug, Opdivo, could slow tumor growth or extend pati...

Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo

Health : Reuters: Health

(Reuters) - Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges...


Copyright © 2016 Regator, LLC